HSAEC1-KT

The immortalized HSAEC1-KT cells show a stable epithelial morphology and differentiated cytokeratin isoforms after over 100 population doublings, express the stem cell marker p63 and high levels of p16INK4a, and have an intact p53 checkpoint pathway (RefRamirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64(24):9027-9034, 2004. PubMed: 15604268).  

The HSAEC1-KT cells also exhibit characteristics of normal cells such as contact inhibition of growth and failure to form soft agar colonies or form tumors in immune compromised mice (RefKalita M, et al. Systems approaches to modeling chronic mucosal inflammation. Biomed. Res. Int. 2013: 505864, 2013. PubMed: 24228254).

TGFβ-treated HSAEC1-KT cells showed an elongated shape with markedly induced F-actin staining. This morphological change of enhanced front-rear polarity and cytoskeletal actin rearrangement are characteristic morphological changes of EMT (epithelial mesenchymal transition) (RefKalita M, et al. Systems approaches to modeling chronic mucosal inflammation. Biomed. Res. Int. 2013: 505864, 2013. PubMed: 24228254).

The HSAEC1-KT cell line was established by infecting primary human small airway epithelial cell culture with human telomerase (hTERT) and mouse cyclin dependent kinase 4 (CDK4) expressing retrovirus constructs and selecting under 250 ng/mL puromycin and 30 ug/mL G418 as described in PMID: 15604268 (RefRamirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64(24):9027-9034, 2004. PubMed: 15604268)

Cytogenetic analysis was performed on G-banded metaphase cells from the human cell line HSAEC1-KT. Several abnormal male near-diploid karyotypes are found: 

Clone 1 demonstrates trisomy 5 with no other aberrations. 47,XY,+5 

Clone 2 demonstrates trisomy 5 and 20 with no other aberrations. 48,XY,+5,+20 

Clone 3 demonstrates trisomy 5, an isochromosome of the long-arm of chromosome 10, resulting in three copies of the chromosome 10 long-arm and only one copy of the short-arm, and trisomy 20. 48,XY,+5,i(10)(p10),+20

Clone 4 demonstrates a deletion on the short-arm of chromosome 10 at band p10, a deletion on the short-arm of chromosome 17 at band p13, and trisomy 20. 47,XY,del(10)(p10),del(17)(p13),+20.

1. Check all containers for leakage or breakage.
2. Remove the frozen cells from the dry ice packaging and immediately place the cells at a temperature below ­-130°C, preferably in liquid nitrogen vapor, until ready for use.

To make the complete culture medium, add SAGM™ SingleQuots™ (Lonza CC-4124) which contains supplements and growth factors (BPE, Hydrocortisone, hEGF, Epinephrine, Transferrin, Insulin, Retinoic Acid, Triiodothyronine, BSA-FAF) to 500 mL bottle of SABM Basal Medium™, phenol red free basal medium (Lonza CC-3119)

1. Prepare a 25 cm² or a 75 cm² culture flask containing the recommended complete culture medium. Prior to the addition of the vial contents, the vessel containing the growth medium should be placed in the incubator for at least 15 minutes to allow the medium to reach its normal pH (7.0 to 7.6) and to avoid excessive alkalinity of the medium during recovery of the cells.
2. Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 minutes).
3. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All operations from this point on should be carried out under strict aseptic conditions.
4. Transfer the vial contents to a centrifuge tube containing 3.0 mL of complete culture medium, mix gently, then slowly add an additional 7 mL of complete growth medium and centrifuge the cell suspension at approximately 1000 rpm for 2 minutes at room temperature.
5. Discard the supernatant and resuspend the cells in 3 mL of fresh growth medium. Count the cells and seed at recommended seeding density.  
6. Incubate the culture at 37°C in a suitable incubator.

1. Remove and discard spent medium.
2. Briefly rinse the cells with Dulbecco's Phosphate Buffered Saline (DPBS, ATCC 30-2200), 1 mL / 25 cm² and discard rinse solution.
3. Add Trypsin-EDTA, at 1 mL / 25 cm², for Primary Cells (ATCC PCS-999-003) to the flask. Incubate at 37°C for 4-6 min (until 90% of the cells have detached).
4. Rapt flask gently to ensure cells are detached.  Add 2% FBS in DPBS at 1 mL / 25 cm² to neutralize the trypsin.
5. Centrifuge cells at 1000rpm for 5 min at room temperature.
6. Remove supernatant. Resuspend pellet in 6.0 to 8.0 mL Complete Growth Medium.
7. Count cells, and seed 8.0 x 10³ to 10.0 x 10³ viable cells/cm² to new culture vessels.

The product is provided 'AS IS' and the viability of ATCC^® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid.  Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.

This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.

While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.

This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.

Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at www.atcc.org.